Hallmarks of constitutive activity were all reversed by a specific PrlR antagonist , which opens potential therapeutic approaches for MFA , or any other disease that could be associated with this mutation in future .
O O O O O O O O O O B-ChemicalEntity I-ChemicalEntity O O O O O O O B-DiseaseOrPhenotypicFeature O O O O O O O O O O O O O O O